Dr Alok Sharma Stem Cell Therapy Treatment for Stroke Dr Alok Sharma Stem Cell Therapy Treatment for Stroke before and after compareson After Stem Cell Therapy 1) Can walk almost 50-60 steps at a time without ex... By: neurogenbsi … Continue reading →

Dr Alok Sharma Stem Cell Therapy Treatment for Muscular Dystrophy Dr Alok Sharma Stem Cell Therapy Treatment for Muscular Dystrophy She is a known case of MD with history of gradual onset of progressive lower extremities muscle weakness noticed since 27 years of age with complaints of imbalance while walking foot drop and difficulty in stair case climbing So she was investigated and muscle biopsy confirmed diagnosis of MD After Stem Cell Therapy 1 Stamina has increased Exercise tolerance has improved 2 She can lift her leg more up while in standing 3 Hip ... By: neurogenbsi … Continue reading →

Dr Alok Sharma Stem Cell Therapy Treatment for Cerebral Palsy Dr Alok Sharma Stem Cell Therapy Treatment for Cerebral Palsy He is a known case of Diplegic CP with history of full term normal delivery (vaccum) delivery a... By: neurogenbsi … Continue reading →

Prolotherapy | PRP | Stem Cell Therapy | The Prolotherapy Institute - prolotherapyinstitute.com Prolotherapy | PRP | Stem Cell Therapy | The Prolotherapy Institute prolotherapyinstitutecom. Uploaded by Guillermo Mata on Mar 11 2013. Suffering from chronic pain Dr Darrow can help Prolotherapy | PRP | Stem Cell Therapy in Southern California Call The Prolotherapy Institute today Call Us Today to Make an Appointment800 7342210. By: Guillermo Mata … Continue reading →

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwire - Mar 13, 2013) - BrainStorm Cell Therapeutics ( OTCQB : BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, will be presenting the initial results of its Phase I/II ALS trial at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, California, from March 16-23.BrainStorm's groundbreaking clinical trial data were selected for one of only twelve oral presentations in the Emerging Science Session on Wednesday, March 20th. The presentation, to be made by Principal Investigator Professor Dimitrios Karussis of the Hadassah Medical Center in Jerusalem, will be the first to make public the outstanding Phase I/II clinical trial safety data and promising initial indications of clinical efficacy observed after treatment with NurOwn, BrainStorm's stem cell therapy candidate for ALS. "We are honored to present these important clinical data at the most prestigious world neurology meeting," commented Professor Karussis. "We are confident that the results observed so far will be indicative of the potential therapeutic benefit of NurOwn cells for treatment of ALS," he added. The American Academy of Neurology Annual Meeting is one of the world's most important annual events for neurologists and … Continue reading →

ROCKVILLE, Md., March 14, 2013 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that CEO and President, Richard Garr, was listed as the 15th most influential person in the stem field in the "Top 50 Global Stem Cell Influencers," published by Total BioPharma, a division of Terrapinn, in advance of the World Stem Cells & Regenerative Medicine Congress 2013, in May. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) The list is the result of a global stem cell community survey to determine the most influential individuals in the field, including researchers, and business and government leaders. About Neuralstem Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, in February 2013, and has submitted recommended Phase II trial protocol to the FDA. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy. In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell … Continue reading →

Stem Cell Orthopedic applauds new studies finding Platelet-Rich Plasma (PRP) therapy helpful in treating osteoarthritis. (PRWEB) March 13, 2013 PRP stem cell therapy is a promising and exciting treatment that takes a concentration of a persons own plasma from their blood, and injects them into areas of their body in need of new growth and tissue repair. This process applied to many sufferers of osteoarthritis has shown to not only relieve their pain and improve their joint function, but studies prove that PRP injections appear to even delay the progression of osteoarthritis in general. As experts in PRP arthritis therapy, Stem Cell Orthopedic has lead the way in improving this groundbreaking treatment option and its applications to treat people around the world in need of its regenerative properties. The Institute of Regenerative and Molecular Orthopaedics is headed by the world-renowned stem cell treatment pioneer, Dr. Joseph Purita. The IRMO are of the few orthopedic practices on earth that utilizes stem cell therapy and PRP therapy with orthopedic surgery. As more and more studies around the world sing the praises of platelet rich plasma therapy, Stem Cell Orthopedic will continue offering this trailblazing treatment to help maximize the recovery of their … Continue reading →

Nanomedicine -- time to bridge the gap from experimental science to product regulation Dr Sonia Trigueros, Co-Director, Oxford Martin Programme on Nanotechnology and Research Fellow in Biological Physics, University of Oxford Professor Sergi Ci... By: 21school … Continue reading →

Vesiculation driven by frustrations in membrane ordering - Supplementary video 1: 38314 Supplementary video 1 (Variation of positions and number of defects on a membrane possessing two beads on increasing the normalized average mean curvature) o... By: dovepress … Continue reading →